Agios Archives - The Cooley's Anemia Foundation

Agios Pharmaceuticals Announces Phase 3 ENERGIZE – Treatment for Thalassemia Patients

Wednesday, January 3rd, 2024

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia January 3, 2024 – Agios Pharmaceuticals, Inc. today announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of […]

: Blog, Front Page, info thalassemia, medical professional, Medical Research, News, person with thalassemia, Webinars
: Agios, agospharmaceuticals, alpha thalassemia, beta-thalassemia, cooleys anemia foundation, energize, i have thalassemia, medical research for thalassemia, pharma, thalassemia, thalassemia care, thalassemia treatment, what is thalassemia

Agios Launches Advocacy Advisory Council for Thalassemia, PK Deficiency, SCD

Tuesday, February 28th, 2023

The council will bring together patients, caregivers and physicians from these communities, which share commonalities in underlying disease pathology, difficulties in transitioning from pediatric to adult care and quality of life concerns.

: Blog, Front Page, News, person with thalassemia
: Agios, beta thalassemia major, biotech, Cooley's anemia, e beta thalassemia, patient advocacy, pharma, PKD, Red Cell Revolution, SCD, Thal Pals, thalassemia

Tag: Agios

Agios Pharmaceuticals Announces Phase 3 ENERGIZE – Treatment for Thalassemia Patients

Agios Launches Advocacy Advisory Council for Thalassemia, PK Deficiency, SCD

Archive Posts